S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Mike Tyson’s Wisdom: Life, Planning, and Resilience
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Mike Tyson’s Wisdom: Life, Planning, and Resilience
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Mike Tyson’s Wisdom: Life, Planning, and Resilience
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
How major US stock indexes fared Friday, 2/23/2024
MarketBeat Week in Review – 2/19 - 2/23
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Closing prices for crude oil, gold and other commodities
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Mike Tyson’s Wisdom: Life, Planning, and Resilience
NASDAQ:JSPRW

Jasper Therapeutics (JSPRW) Stock Price, News & Analysis

$0.20
+0.02 (+10.81%)
(As of 02/23/2024 ET)
Today's Range
$0.17
$0.22
50-Day Range
$0.04
$0.21
52-Week Range
$0.04
$0.38
Volume
16,613 shs
Average Volume
38,177 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

JSPRW Stock Price History

JSPRW Stock News Headlines

See More Headlines
Receive JSPRW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:JSPRW
Web
N/A
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Ronald A. Martell (Age 62)
    President, CEO & Director
    Comp: $892.45k
  • Dr. Judith Anne Shizuru M.D. (Age 68)
    Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director
    Comp: $291.25k
  • Mr. Jeetinder Singh Mahal M.B.A. (Age 52)
    Chief Operating Officer
    Comp: $579.46k
  • Mr. Herbert C. Cross (Age 52)
    CFO & Corporate Secretary
  • Dr. Luca Di Noto Ph.D.
    Senior Vice President of Technical Operations
  • Mr. David Ku M.D.
    Vice President of Corporate Development, Portfolio Strategy & Management
  • Mr. Matthew Ford
    Vice President of Human Resources
  • Dr. Wendy Pang M.D.
    Ph.D., Senior Vice President of Research & Translational Medicine
  • Dr. Edwin Jonathan Tucker M.D. (Age 52)
    Chief Medical Officer
  • Ms. Patricia Carlos
    Senior Vice President of Regulatory Affairs & Quality














JSPRW Stock Analysis - Frequently Asked Questions

How have JSPRW shares performed in 2024?

Jasper Therapeutics' stock was trading at $0.08 at the beginning of the year. Since then, JSPRW shares have increased by 156.3% and is now trading at $0.2050.
View the best growth stocks for 2024 here
.

Are investors shorting Jasper Therapeutics?

Jasper Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 7,400 shares, a decrease of 66.4% from the January 15th total of 22,000 shares. Based on an average daily volume of 24,600 shares, the days-to-cover ratio is presently 0.3 days.
View Jasper Therapeutics' Short Interest
.

Who are Jasper Therapeutics' major shareholders?

Jasper Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Jasper Therapeutics?

Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JSPRW) was last updated on 2/24/2024 by MarketBeat.com Staff